The DOI matches its Crossref record.
Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome
Open accessAbstract
Background—: It has been shown that losartan reduces aortic dilatation in patients with Marfan syndrome. However, treatment response is highly variable. This study investigates losartan effectiveness in genetically classified subgroups. Methods and Results—: In this predefined substudy of COMPARE, Marfan patients were randomized to daily receive losartan 100 mg or no losartan. Aortic root dimensions were measured by MRI at baseline and after 3 years. FBN1 mutations were classified based on fibrillin-1 protein effect into (1) haploinsufficiency, decreased amount of normal fibrillin-1, or (2) dominant negative, normal fibrillin-1 abundance with mutant fibrillin-1 incorporated in the matrix. A pathogenic FBN1 mutation was found in 117 patients, of whom 79 patients were positive for a dominant negative mutation (67.5%) and 38 for a mutation causing haploinsufficiency (32.5%). Baseline characteristics between treatment groups were similar. Overall, losartan significantly reduced aortic root dilatation rate (no losartan, 1.3±1.5 mm/3 years, n=59 versus losartan, 0.8±1.4 mm/3 years, n=58; P =0.009). However, losartan reduced only aortic root dilatation rate in haploinsufficient patients (no losartan, 1.8±1.5 mm/3 years, n=21 versus losartan 0.5±0.8 mm/3 years, n=17; P =0.001) and not in dominant negative patients (no losartan, 1.2±1.7 mm/3 years, n=38 versus losartan 0.8±1.3 mm/3 years, n=41; P =0.197). Conclusions—: Marfan patients with haploinsufficient FBN1 mutations seem to be more responsive to losartan therapy for inhibition of aortic root dilatation rate compared with dominant negative patients. Additional treatment strategies are needed in Marfan patients with dominant negative FBN1 mutations. Clinical Trial Registration—: http://www.trialregister.nl/trialreg/index.asp ; Unique Identifier: NTR1423.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Milewicz, D. M., Braverman, A. C., De Backer, J., Morris, S. A., Boileau, C., Maumenee, I. H., Jondeau, G., Evangelista, A., & Pyeritz, R. E. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00298-7 · Cited by 305
Hereditary Influence in Thoracic Aortic Aneurysm and Dissection
Isselbacher, E. M., Lino Cardenas, C. L., & Lindsay, M. E. (2016) · Circulation · doi:10.1161/circulationaha.116.009762 · Cited by 262
Thomson, J., Singh, M., Eckersley, A., Cain, S. A., Sherratt, M. J., & Baldock, C. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2018.07.016 · Cited by 170
Metadata
- Authors
- Franken, R., den Hartog, A. W., Radonic, T., Micha, D., Maugeri, A., van Dijk, F. S., Meijers-Heijboer, H. E., Timmermans, J., Scholte, A. J., van den Berg, M. P., Groenink, M., Mulder, B. J. M., Zwinderman, A. H., de Waard, V., & Pals, G.
- Venue
- Circulation: Cardiovascular Genetics
- Published
- 2015-04
- Volume
- 8
- Issue
- 2
- Pages
- 383-388
- ISSN
- 1942-325X (ISSN-L)
- 1942-3268
- OpenAlex
- W2162249260
- Cited by
- 173
- References
- 0
- FWCI
- 15.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. https://app.cochat.ai/papers/10.1161/circgenetics.114.000950
- The paper
- Franken, R., den Hartog, A. W., Radonic, T., Micha, D., Maugeri, A., van Dijk, F. S., Meijers-Heijboer, H. E., Timmermans, J., Scholte, A. J., van den Berg, M. P., Groenink, M., Mulder, B. J. M., Zwinderman, A. H., de Waard, V., & Pals, G. (2015). Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. Circulation: Cardiovascular Genetics. https://doi.org/10.1161/circgenetics.114.000950
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.